Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.39) per share which beat the analyst consensus estimate of $(1.40) by 0.71 percent. This is a 67.47 percent decrease over losses of $(0.83) per share from the same period last year.